medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2017, Number 3

<< Back Next >>

Rev Mex Patol Clin Med Lab 2017; 64 (3)

Diabetes mellitus as a predisposing factor for tuberculosis

Hernández-Mendoza L, Bravo-Román E, García-Macedonio JE, García-González R

Language: Spanish
References: 70
Page: 125-134
PDF size: 342.15 Kb.


ABSTRACT

Tuberculosis is a disease to which most of the Mexican population has been exposed and, therefore, presents a primoinfection with it. Diabetes mellitus is part of the metabolic syndrome, whose prevalence is increasing every day in the developing countries. The presence of both diseases is now increasing its frequency in our country- In cases of comorbidity, diabetes mellitus directly affects the cellular and humoral immune response of the host against tubercle bacilli, thus causing exacerbation of the clinical manifestations of tuberculosis; likewise, the inflammatory condition of the patient increases his glycaemia and hinders its control, coupled with the hyperglycaemic effect of some TB drugs.


REFERENCES

  1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle. 1991; 72 (1): 1-6.

  2. Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ. 1992; 70 (2): 149-159.

  3. Daniel VS, Daniel TM. Old Testament biblical references to tuberculosis. Clin Infect Dis. 1999; 29 (6): 1557-1558.

  4. Organización Panamericana de la Salud. Manual para el diagnóstico bacteriológico de la tuberculosis; normas y guía técnica. Parte I. Baciloscopia. Washington, DC: Organización Panamericana de la Salud; 2008.

  5. Global tuberculosis report 2014. France: World Health Organization; 2014.

  6. García-González R, Cervantes-García E, Reyes-Torres A. Tuberculosis, un desafío del siglo XXI. Rev Latinoam Patol Clin Med Lab. 2016; 63 (2): 91-99.

  7. Jones BE, Ryu R, Yang Z, Cave MD, Pogoda JM, Otaya M et al. Chest radiographic findings in patients with tuberculosis with recent or remote infection. Am J Respir Crit Care Med. 1997; 156 (4 Pt 1): 1270-1273.

  8. Molina P, Espinoza A. Tuberculosis pleural. Rev Costarric Cienc Méd. 2005; 26 (3-4): 45-50.

  9. Farga V, Caminero JA. Tuberculosis. 3.a edición. Santiago de Chile: Mediterráneo; 2012.

  10. Tay-Zavala J, Gutiérrez-Quiróz M, López-Martínez R, Molina-López J, Manjarrez-Zavala EM. Microbiología y parasitología médicas de Tay. 4.a ed. México: Méndez editores; 2012.

  11. Ferreiro L, San José E, Valdés L. Derrame pleural tuberculoso. Arch Bronconeumol. 2014; 50 (10): 435-443.

  12. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins & Cotran. Patología estructural y funcional. 9.a ed. Madrid, España: Elsevier; 2015. pp. 370-371.

  13. OMS. Tuberculosis. Nota descriptiva No 104. Marzo de 2016.

  14. García-González R, Nájera-Garduño MC, Hernández-Ramírez A. Tuberculosis, enfermedad no erradicada. Rev Hosp Jua Méx. 2004; 71 (4): 158-166.

  15. Cardona PJ, Ivanyi J. The secret trumps, impelling the pathogenicity of tubercle bacilli. Enferm Infecc Microbiol Clin. 2011; 29 Suppl 1: 14-19.

  16. Santín-Cerezales M, Navas-Elorza E. Tuberculosis in special populations. Enferm Infecc Microbiol Clin. 2011; 29 Supl 1: 20-25.

  17. Chávez-Galán L, Arenas-Del Ángel MC, Sada-Ovallea I, Lascurain R. Principales mecanismos de evasión de la respuesta inmune por Mycobacterium tuberculosis. Gac Méd Méx. 2009; 145 (4): 323-328.

  18. Lenaerts A, Barry CE 3rd, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 2015; 264 (1): 288-307.

  19. Dannenberg AM Jr. Immunopathogenesis of pulmonary tuberculosis. Hosp Pract (Off Ed). 1993; 28 (1): 51-58.

  20. Dannenberg AM. Pathophysiology: basic aspect. In: Schlossberg D (Ed). Tuberculosis and non tuberculous mycobacterial infections. 4th edition. Philadelphia, Pennsylvania: WB Saunders Company; 1999. pp. 17-47.

  21. Navarro AN, López PL, Sandoval CJ. La gran simuladora. Semergen. 2015; 41 (Espec Congr): 1152.

  22. Moreno-Pérez D, Andrés Martín A, Altet-Gómez N, Baquero-Artigao F, Escribano-Montaner A, Gómez-Pastrana Durán D et al. Diagnóstico de la tuberculosis en la edad pediátrica. Documento de consenso de la Sociedad Española de Infectología Pediátrica (SEIP) y la Sociedad Española de Neumología Pediátrica (SENP). An Pediatr (Barc). 2010; 73 (3): 143e1-143e14.

  23. Caminero JA. ¿Podemos mejorar la prevención de la tuberculosis? Enferm Infect Microbiol Clin. 2010; 28 (4): 211-214.

  24. Mukherjee A, Lodha R, Kabra SK. Changing trends in childhood tuberculosis. Indian J Pediatr. 2011; 78 (3): 328-333.

  25. Cerrato-Varela CN, Pineda KP. Tuberculosis abdominal en paciente con VIH/SIDA. Rev Méd Hondur. 2010; 78 (1): 21-24.

  26. Drobniewski FA, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis. 2003; 3 (3): 141-147.

  27. Organización Panamericana de la Salud. Manual para el diagnóstico bacteriológico de la tuberculosis; normas y guía técnica. Parte II. Washington, DC: Organización Panamericana de la Salud; 2008.

  28. García-González R, Lara-Hernández A, Nájera-Garduño MC, Arzate-Barbosa P. Detección de Mycobacterium tuberculosis con el empleo de dos sistemas de cultivo y su confirmación con la reacción en cadena de la polimerasa. Rev Enf Infec Ped. 1999; 12: 323-328.

  29. Barriga-Angulo G, López-Álvarez L, Ramírez-Cruz F, Monzalvo-Álvarez ME, Villagrán-Gama JA, Rodríguez-Arreguín E et al. Experiencia de un laboratorio de tercer nivel de atención en el diagnóstico de infecciones por micobacterias. Rev Latinoamer Patol Clin. 2014; 61 (3): 156-162.

  30. Naik N. Diagnosis and treatment of tuberculosis of the central nervous system in children. Pediatric Infectious Diseases. 2012; 4 (2): 51-56.

  31. Nikam C, Rodrigues C. Xpert MTB/RIF: The newly endorsed TB diagnostic. Pediatric Infectious Diseases 2014; 6: 75-78.

  32. Tarrago A, Jiménez S, Sánchez A, Arroyo A, Aracil J, Cañete A. Brote de tuberculosis en un colegio de primaria: descripción y consideraciones sobre el valor del jugo gástrico en el manejo de microepidemias. Enferm Infecc Microbiol Clin. 2011; 29 (2): 90-95.

  33. Kang DD, Lin Y, Moreno JR, Randall TD, Khader SA. Profiling early lung immune responses in the mouse model of tuberculosis. PLoS One. 2011; 6 (1): e16161.

  34. Wolf AJ, Linas B, Trevejo-Nuñez GJ, Kincaid E, Tamura T, Takatsu K et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol. 2007; 179 (4): 2509-2519.

  35. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol. 2012; 12 (8): 581-591.

  36. Peddireddy V, Doddam SN, Ahmed N. Mycobacterial dormancy systems and host responses in tuberculosis. Front Immunol. 2017; 8: 84.

  37. Banaiee N, Kincaid EZ, Buchwald U, Jacobs WR Jr, Ernst JD. Potent inhibition of macrophage responses to IFN-gamma by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2. J Immunol. 2006; 176 (5): 3019-3027.

  38. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med. 2005; 202 (12): 1715-1724.

  39. Bozzano F, Marras F, De Maria A. Immunology of tuberculosis. Mediterr J Hematol Infect Dis. 2014; 6 (1): e2014027.

  40. Miller BH, Fratti RA, Poschet JF, Timmins GS, Master SS, Burgos M et al. Mycobacteria inhibit nitric oxide synthase recruitment to phagosomes during macrophage infection. Infect Immun. 2004; 72 (5): 2872-2878.

  41. Cooper AM, Mayer-Barber KD, Sher A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 2011; 4 (3): 252-260.

  42. Blomgran R, Desvignes L, Briken V, Ernst JD. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe. 2012; 11 (1): 81-90.

  43. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med. 2010; 207 (7): 1409-1420.

  44. Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol. 2007; 5 (1): 39-47.

  45. International Diabetes Federation. Diabetes Atlas.

  46. Warren E, Teskey G, Venketaraman V. Effector mechanisms of neutrophils within the innate immune system in response to Mycobacterium tuberculosis infection. J Clin Med. 2017; 6 (2). pii: E15. doi: 10.3390/jcm6020015.

  47. Van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002; 15 (2): 294-309.

  48. Nandi B, Behar SM. Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection. J Exp Med. 2011; 208 (11): 2251-2262.

  49. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013; 368 (8): 745-755.

  50. Guía de práctica clínica. Diagnóstico y tratamiento de casos nuevos de tuberculosis pulmonar. México: Secretaría de Salud; 2009.

  51. Restrepo BI, Fisher-Hoch SP, Crespo JG, Whitney E, Perez A, Smith B et al. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect. 2007; 135 (3): 483-491.

  52. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11 (2): 98-107.

  53. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med. 2005; 11 (2): 183-190.

  54. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997; 40 (11): 1286-1292.

  55. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011; 11 (11): 738-749.

  56. Jagannathan M, McDonnell M, Liang Y, Hasturk H, Hetzel J, Rubin D et al. Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia. 2010; 53 (7): 1461-1471.

  57. Ayilavarapu S, Kantarci A, Fredman G, Turkoglu O, Omori K, Liu H et al. Diabetes-induced oxidative stress is mediated by Ca2+-independent phospholipase A2 in neutrophils. J Immunol. 2010; 184 (3): 1507-1515.

  58. Stegenga ME, van der Crabben SN, Dessing MC, Pater JM, van den Pangaart PS, de Vos AF et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med. 2008; 25 (2): 157-164.

  59. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009; 15 (8): 930-939.

  60. Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A. 2010; 107 (21): 9765-9770.

  61. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A et al. Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 2001; 50 (8): 1683-1690.

  62. Schumann DM, Maedler K, Franklin I, Konrad D, Størling J, Böni-Schnetzler M et al. The Fas pathway is involved in pancreatic β cell secretory function. Proc Natl Acad Sci U S A. 2007; 104 (8): 2861-2866.

  63. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002; 110 (6): 851-860.

  64. Deng C, Wang X, Liao Y. Current recommendations on managing tuberculosis patients with diabetes & its epidemiology. Microb Pathog. 2016; 92: 43-45.

  65. Warner DF, Koch A, Mizrahi V. Diversity and disease pathogenesis in Mycobacterium tuberculosis. Trends Microbiol. 2015; 23 (1): 14-21.

  66. Rodríguez-Rodríguez S, Ruy-Díaz-Reynoso SJA, Vázquez-López R. Tuberculosis concomitant with diabetes. Rev Med Hosp Gen Méx. 2015; 78 (4): 183-187.

  67. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009; 2 (5-6): 231-237.

  68. García-Elorriaga G, Del Rey-Pineda G. Type 2 diabetes mellitus as a risk factor for tuberculosis. J Mycobac Dis. 2014; 4: 144.

  69. Triunfo S, Lanzone A, Lindqvist PG. Low maternal circulating levels of vitamin D as potential determinant in the development of gestational diabetes mellitus. J Endocrinol Invest. 2017. doi: 10.1007/s40618-017-0696-9. [Epub ahead of print]

  70. Islam LN, Hossain M, Zahid MSH. Complement mediated bactericidal activity and humoral immune response in type 2 diabetes mellitus. Int J Diabetes & Metabolism. 2006; 14: 92-97.




2020     |     www.medigraphic.com